ValuEngine upgraded shares of Halyard Health (NYSE:HYH) from a buy rating to a strong-buy rating in a research note published on Friday.
Several other research analysts have also commented on the company. Zacks Investment Research lowered Halyard Health from a buy rating to a hold rating in a research report on Wednesday, January 3rd. KeyCorp upgraded Halyard Health from a sector weight rating to an overweight rating in a research report on Thursday, April 5th. One research analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. Halyard Health currently has a consensus rating of Buy and a consensus target price of $49.33.
HYH stock opened at $47.10 on Friday. The company has a current ratio of 2.98, a quick ratio of 2.74 and a debt-to-equity ratio of 0.45. Halyard Health has a 52-week low of $35.24 and a 52-week high of $50.99. The company has a market cap of $2,219.79, a price-to-earnings ratio of 20.04, a price-to-earnings-growth ratio of 5.54 and a beta of 1.62.
Halyard Health (NYSE:HYH) last posted its quarterly earnings data on Tuesday, February 27th. The medical instruments supplier reported $0.73 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.50 by $0.23. Halyard Health had a return on equity of 6.98% and a net margin of 5.82%. The company had revenue of $428.10 million for the quarter, compared to the consensus estimate of $413.94 million. During the same period in the previous year, the business earned $0.50 EPS. Halyard Health’s revenue for the quarter was up 4.4% compared to the same quarter last year. equities analysts forecast that Halyard Health will post 0.96 EPS for the current fiscal year.
Several institutional investors and hedge funds have recently modified their holdings of the company. Xact Kapitalforvaltning AB acquired a new position in Halyard Health during the 4th quarter valued at approximately $250,000. MetLife Investment Advisors LLC acquired a new position in Halyard Health during the 4th quarter valued at approximately $2,332,000. Macquarie Group Ltd. boosted its position in Halyard Health by 103.0% during the 4th quarter. Macquarie Group Ltd. now owns 859,281 shares of the medical instruments supplier’s stock valued at $39,681,000 after purchasing an additional 435,935 shares during the period. Vident Investment Advisory LLC boosted its position in Halyard Health by 6.5% during the 4th quarter. Vident Investment Advisory LLC now owns 67,997 shares of the medical instruments supplier’s stock valued at $3,140,000 after purchasing an additional 4,147 shares during the period. Finally, Jane Street Group LLC boosted its position in Halyard Health by 88.0% during the 4th quarter. Jane Street Group LLC now owns 8,808 shares of the medical instruments supplier’s stock valued at $407,000 after purchasing an additional 4,124 shares during the period. Institutional investors own 91.32% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Halyard Health (HYH) Raised to Strong-Buy at ValuEngine” was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece of content on another domain, it was stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/04/16/halyard-health-hyh-raised-to-strong-buy-at-valuengine.html.
About Halyard Health
Halyard Health, Inc is a medical technology company. The Company operates through two segments: Medical Devices and Surgical and Infection Prevention (S&IP). The Medical Devices segment provides a portfolio of product offerings focused on pain management, respiratory and digestive health. The S&IP segment provides healthcare supplies and solutions that target the prevention of healthcare-associated infections.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Halyard Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halyard Health and related companies with MarketBeat.com's FREE daily email newsletter.